Diffuse Large B-cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
Eligible for screening study DCP 001
This study is open to FACT-accredited institutions only.
Site Delegation of Tasks Log required prior to registration of any patients.